Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Caribou Biosciences (CRBU) EPS (Weighted Average and Diluted) (2021 - 2025)

Caribou Biosciences has reported EPS (Weighted Average and Diluted) over the past 5 years, most recently at -$0.28 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 28.21% to -$0.28 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.59 through Dec 2025, up 3.64% year-over-year, with the annual reading at -$1.59 for FY2025, 3.64% up from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.28 for Q4 2025 at Caribou Biosciences, up from -$0.3 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.09 in Q4 2021 and troughed at -$1.39 in Q2 2021.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.43 (2025), against an average of -$0.43.
  • Year-over-year, EPS (Weighted Average and Diluted) tumbled 600.0% in 2022 and then surged 72.73% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.09 in 2021, then tumbled by 600.0% to -$0.45 in 2022, then increased by 11.11% to -$0.4 in 2023, then increased by 2.5% to -$0.39 in 2024, then increased by 28.21% to -$0.28 in 2025.
  • Per Business Quant, the three most recent readings for CRBU's EPS (Weighted Average and Diluted) are -$0.28 (Q4 2025), -$0.3 (Q3 2025), and -$0.58 (Q2 2025).